Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate (marketed as Truvada) Information

On July 16, 2012, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

Regulatory History and Labeling from Drugs@FDA

Page Last Updated: 07/10/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.